Procedures
HIV testing and HIV
CERVICAL CANCER
Potential participants completed eligibility screening with a provider, including a detailed medical history, collection of external genital (labial/vulvar/perineal), lateral vaginal, and cervical swabs for HPV DNA testing, and serum for HPV antibody testing. Participants received cytological screening for cervical cancer screening at enrollment. Sexual and reproductive health services (contraception, STI diagnosis and treatment, HIV testing and HIV pre-exposure prophylaxis) were offered at enrollment and every visit. Participants also received counseling including services for mental health. All questionnaires used electronic case report forms (eCRFs) (DFexplore Software, DF/Net Research).Participants had study visits at months 3, 6 and then every 6 months for up to 36 months. Providers administered clinical questionnaires and collected a cervical swab at each 6-month visit. Participants self-collected vaginal swabs using validated instructions at month 3; self-collected swabs, which have similar accuracy compared to provider-collected cervical swabsFollowing dissemination and WHO review of the month 18 primary results, participants were offered vaccination at their next study visit, which was at either month 30 or 36, so as not to delay vaccine receipt. Participants provided a final analysis cervical swab before vaccination. Participants in the meningococcal group received the nonavalent HPV vaccine and those in the HPV vaccine groups received the meningococcal vaccine.